Annual data on the proportion of adults in Great Britain who smoke cigarettes, cigarette consumption, the proportion who have never smoked cigarettes and the proportion of smokers who have quit by sex and age over time.

Annual data and annual historic data on the proportion of adults who currently smoke, the proportion of ex-smokers and proportion of those who have never smoked, by sex and age.

Cigarette smoking among adults including the proportion of people who smoke, their demographic breakdowns, changes over time, and e-cigarettes.

This dataset contains three smoking related indicators. Rates of self reported four-week smoking quitters Smoking quit rates per 100,000 available from the HNA. - These quarterly reports present provisional results from the monitoring of the NHS Stop Smoking Services (NHS SSS) in England. This report includes information on the number of people setting a quit date and the number who successfully quit at the 4 week follow-up. Data for London presented with England comparator. PCT level data available from NHS. Number of Deaths Attributable to Smoking per 100,000 population by borough Deaths attributable to smoking, directly age-sex standardised rate for persons aged 35 years +. Causes of death considered to be related to smoking are: various cancers, cardiovascular and respiratory diseases, and diseases of the digestive system. Numbers of adults smoking by borough Prevalence of smoking among persons aged 18 years and over. - Population who currently smoke, are ex-smokers, or never smoked by borough. This includes cigarette, cigar or pipe smokers. Data by age is also provided for London with a UK comparator. Relevant links: http://www.hscic.gov.uk/Article/1685 http://www.apho.org.uk/default.aspx?QN=HP_DATATABLES

United Kingdom UK: Smoking Prevalence: Females: % of Adults data was reported at 20.000 % in 2016. This records a decrease from the previous number of 20.700 % for 2015. United Kingdom UK: Smoking Prevalence: Females: % of Adults data is updated yearly, averaging 23.400 % from Dec 2000 (Median) to 2016, with 9 observations. The data reached an all-time high of 37.500 % in 2000 and a record low of 20.000 % in 2016. United Kingdom UK: Smoking Prevalence: Females: % of Adults data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Prevalence of smoking, female is the percentage of women ages 15 and over who currently smoke any tobacco product on a daily or non-daily basis. It excludes smokeless tobacco use. The rates are age-standardized.; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

United Kingdom UK: Smoking Prevalence: Total: % of Adults: Aged 15+ data was reported at 22.300 % in 2016. This records a decrease from the previous number of 23.100 % for 2015. United Kingdom UK: Smoking Prevalence: Total: % of Adults: Aged 15+ data is updated yearly, averaging 25.500 % from Dec 2000 (Median) to 2016, with 9 observations. The data reached an all-time high of 38.200 % in 2000 and a record low of 22.300 % in 2016. United Kingdom UK: Smoking Prevalence: Total: % of Adults: Aged 15+ data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Prevalence of smoking is the percentage of men and women ages 15 and over who currently smoke any tobacco product on a daily or non-daily basis. It excludes smokeless tobacco use. The rates are age-standardized.; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

This dataset captures the percentage of mothers in England who are recorded as smokers at the time of delivery. It is a key maternal health indicator, reflecting the prevalence of smoking among pregnant women at the point of childbirth. The data is collected through the NHS England Statistics on Women's Smoking at Time of Delivery (SATOD) and is used to monitor progress in reducing smoking during pregnancy.

Rationale

Smoking during pregnancy poses significant health risks to both the mother and the baby, including increased chances of miscarriage, premature birth, and low birth weight. Reducing the percentage of mothers who smoke at the time of delivery is a public health priority. This indicator supports efforts to improve maternal and child health outcomes by tracking smoking prevalence and informing targeted interventions.

Numerator

The numerator is the number of women known to be smokers at the time of delivery, as recorded in maternity services data.

Denominator

The denominator is also the number of women known to be smokers at the time of delivery, as reported in the same dataset. This suggests the indicator is expressed as a percentage of known cases, excluding unknowns.

Caveats

This indicator is based on observational data and may be subject to measurement bias. Additionally, known IT issues have led to high levels of unknown smoking status in the source data. These issues are expected to improve over time as data systems become more robust and consistent.

External References

More information is available from the following source:

Statistics on Women's Smoking Status at Time of Delivery - NHS Digital

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.

This dataset presents the prevalence of smoking among adults aged 18 and over who have a long-term mental health condition. It is derived from the GP Patient Survey (GPPS) and reflects the proportion of individuals within this group who self-report as current smokers. The indicator provides insight into smoking behaviours among a population known to experience significant health inequalities.

Rationale

Adults with long-term mental health conditions are more likely to smoke than the general population, contributing to poorer physical health outcomes and reduced life expectancy. Reducing smoking prevalence in this group is a public health priority. This indicator supports efforts to monitor and address health disparities through targeted smoking cessation interventions.

Numerator

The numerator is the sum of individual weighted counts of respondents who self-report as current smokers (responses 3 or 4 to question Q55) and who also report having a long-term mental health condition (Q31_14 = true) in the GP Patient Survey.

Denominator

The denominator is the sum of individual weighted counts of all respondents who provided valid responses to both the smoking status (Q55) and long-term medical conditions (Q31) questions in the GP Patient Survey.

Caveats

No specific caveats are noted for this indicator. However, as with all self-reported survey data, responses may be subject to reporting bias or inaccuracies in self-assessment.

External References

More information is available from the following source:

Fingertips Public Health Profiles

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.

Annual data on the proportion of adults in Great Britain who use e-cigarettes, by different characteristics such as age, sex and cigarette smoking status.

This dataset includes information regarding proportion who smoke cigarettes, cigarette consumption, the proportion who have never smoked cigarettes and proportion of smokers who have quit by sex/age over time in Great Britain from 1974 to 2019.

BackgroundSmoking is a risk factor for chronic obstructive pulmonary disease (COPD). Few studies have assessed the causal relationship between smoking and COPD using Mendelian randomization.MethodsExposure and outcome datasets were obtained from the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/). The exposure data set includes smoking (ever smoke, smoking/smokers in household, exposure to tobacco smoke at home). The outcome data set includes COPD susceptibility and acute COPD admissions. The main methods of Mendelian randomization analysis are weighted median method and MR-Egger method. Heterogeneity and polymorphism analyses were performed to ensure the accuracy of the results.Reslutsever smoke increased the risk of COPD prevalence, and ever smoke and smoking/smokers in household increased the risk of acute COPD admission. ConclusionTherefore, we should enhance the management of nonpharmacological prescription of COPD to reduce the individual incidence.

The Smoking, Drinking and Drug Use among Young People surveys began in 1982, under the name Smoking among Secondary Schoolchildren. The series initially aimed to provide national estimates of the proportion of secondary schoolchildren aged 11-15 who smoked, and to describe their smoking behaviour. Similar surveys were carried out every two years until 1998 to monitor trends in the prevalence of cigarette smoking. The survey then moved to an annual cycle, and questions on alcohol consumption and drug use were included. The name of the series changed to Smoking, Drinking and Drug Use among Young Teenagers to reflect this widened focus. In 2000, the series title changed, to Smoking, Drinking and Drug Use among Young People. NHS Digital (formerly the Information Centre for Health and Social Care) took over from the Department of Health as sponsors and publishers of the survey series from 2005. From 2014 onwards, the series changed to a biennial one, with no survey taking place in 2015, 2017 or 2019.In some years, the surveys have been carried out in Scotland and Wales as well as England, to provide separate national estimates for these countries. In 2002, following a review of Scotland's future information needs in relation to drug misuse among schoolchildren, a separate Scottish series, Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) was established by the Scottish Executive. The main aim of the 1988 survey, which covered England only, was to continue the series of estimates of the prevalence of cigarette smoking among secondary school children and to draw attention to any changes in behaviour. However, one feature in particular of the 1988 survey distinguishes it from earlier surveys in the series - saliva specimens were obtained from half of the sample. These were analysed for the presence of cotinine, which is a metabolite of nicotine, and is a measure of exposure to tobacco. The main purpose of this was to enable some validation of the self-reported smoking data. The dataset includes variables from the questionnaire, diary and cotinine analysis. Topics covered in the questionnaire include: smoking behaviour, purchase of cigarettes, whether adults in household smoke, knowledge/use of Skoal Bandits (a type of chewing tobacco product), health education lessons in school, demographic characteristics. In addition, a short section of questions about drinking and alcohol use was included. For the diary, pupils were asked to record by retrospective recall all cigarettes smoked in the previous seven days.

BackgroundChildren's exposure to secondhand smoke (SHS) has been causally linked to a number of childhood morbidities and mortalities. Over 50% of UK children whose parents are smokers are regularly exposed to SHS at home. No previous review has identified the factors associated with children's SHS exposure in the home.AimTo identify by systematic review, the factors which are associated with children's SHS exposure in the home, determined by parent or child reports and/or biochemically validated measures including cotinine, carbon monoxide or home air particulate matter.MethodsElectronic searches of MEDLINE, EMBASE, PsychINFO, CINAHL and Web of Knowledge to July 2014, and hand searches of reference lists from publications included in the review were conducted.FindingsForty one studies were included in the review. Parental smoking, low socioeconomic status and being less educated were all frequently and consistently found to be independently associated with children's SHS exposure in the home. Children whose parents held more negative attitudes towards SHS were less likely to be exposed. Associations were strongest for parental cigarette smoking status; compared to children of non-smokers, those whose mothers or both parents smoked were between two and 13 times more likely to be exposed to SHS.ConclusionMultiple factors are associated with child SHS exposure in the home; the best way to reduce child SHS exposure in the home is for smoking parents to quit. If parents are unable or unwilling to stop smoking, they should instigate smoke-free homes. Interventions targeted towards the socially disadvantaged parents aiming to change attitudes to smoking in the presence of children and providing practical support to help parents smoke outside the home may be beneficial.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

As part of current harm reduction strategies, candidate modified risk tobacco products (MRTP)s are developed to offer adult smokers who want to continue using tobacco products as an alternative to cigarettes while potentially reducing individual risk and population harm compared to smoking cigarettes. One of these candidate MRTPs is the Tobacco Heating System (THS) 2.2 which does not burn tobacco, but instead heats it, thus producing significantly reduced levels of harmful and potentially harmful constituents (HPHC)s compared with combustible cigarettes (CC). The assessment of MRTPs against combustible cigarettes requires the establishment of exposure-response markers. Biomarkers derived from blood offer for the general population a less invasive alternative than sampling the primary site, such as the airways. Various diseases and exposures, including cigarette smoke, have been shown to alter the molecular profile of the blood. Leveraging this fact, a whole blood derived gene signature that can distinguish current smokers from either non-smokers or former smokers with high specificity and sensitivity was previously reported. Four controlled, parallel randomized groups, open-label clinical studies were conducted with subjects randomized to three groups: (1) switching from CCs to THS2.2 (or its mentholated version, respectively); (2) continuous use of CC; or (3) smoking abstinence. These studies had an investigational period of five days in confinement which was followed by an 85 day ambulatory period for two of them. By measuring biomarkers of exposure to selected HPHCs, these studies showed a consistent reduced exposure in subjects that either stopped smoking or switched to THS2.2 (including mentholated version), compared with subjects who continued smoking their own cigarettes at both day 5 and at day 90. To complement the classical exposure measurements, we tested the small signature consisting of only 11 genes on the blood transcriptome of subjects enrolled in the clinical studies. We show that in all four clinical studies tested, the signature scores were consistently reduced in subjects that either stopped smoking or switched to THS2.2 compared with subjects who continued smoking their conventional tobacco products at both day 6 and at day 91.